The White House on Feb. 5 launched TrumpRx, a direct-to-consumer website aimed at reducing prescription drug costs by linking patients to manufacturer discounts — but many listed drugs are available for less elsewhere.
The site primarily targets uninsured patients or those lacking coverage for high-cost drugs such as GLP-1s and fertility treatments. TrumpRx even warns users, “If you have insurance, check your copay first — it may be even lower,” according to a Feb. 6 report from The New York Times.
The platform lists 43 brand-name medications and directs users to drugmaker websites or provides printable coupons. At launch, five companies participated: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer.
Discounted drugs on TrumpRx include Wegovy pills at $149 and Zepbound at $299 — prices marketed as steep reductions from retail list prices. But many of these medications are already available for less through insurance, generics or third-party tools such as GoodRx, according to a Feb. 6 report from CNBC.
Novo Nordisk, for example, priced Ozempic at $350 per month through TrumpRx. Yet in Medicare Part D, average brand-name drug discounts reach 40% off list prices, and Medicaid discounts exceed 75%, CNBC reported.
Although the platform may offer savings for some cash-paying patients, pricing comparisons suggest most insured Americans are still likely to find lower costs elsewhere.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.